This series on “Peritoneal Carcinomatosis: History and Future” is edited by Dr. Andrew M. Blakely and Dr. Oliver S. Eng. The main purposes of this series are 1) to provide incidence, prevalence, and demographics of peritoneal carcinomatosis, 2) to summarize historical context of the treatment of peritoneal surface malignancies, 3) to describe upcoming advances in the care of peritoneal surface malignancies.
Oliver S Eng, MD
Section of General Surgery and Surgical Oncology, Department of Surgery, University of Chicago, Chicago, IL, USA
Dr. Eng is a gastrointestinal surgical oncologist and Assistant Professor of Surgery at the University of Chicago. He specializes in the management of locally advanced and metastatic disease, with a focus on peritoneal metastases, often utilizing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Dr. Eng completed his medical education and general surgery training at Rutgers University, Robert Wood Johnson Medical School, followed by a fellowship in complex general surgical oncology at City of Hope National Medical Center. His research centers on better understanding the molecular and immunologic characteristics of peritoneal tumors, as well as optimizing outcomes and care for cancer patients. His work has been presented nationally and internationally, and he is the principal investigator or co-investigator on multiple clinical trials. He has co-authored many peer-reviewed publications, book chapters, and serves on the editorial board and as a reviewer for a variety of scientific journals.
Andrew M. Blakely
Surgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Dr. Blakely is a gastrointestinal surgical oncologist and Assistant Research Physician at the National Cancer Institute. He specializes in the management of peritoneal surface malignancies, soft tissue sarcomas, and gastroenteropancreatic neuroendocrine tumors. Dr. Blakely completed a Bachelor of Science in Biomedical Engineering followed by medical school at Drexel University. He went on to general surgery residency at Brown University. During residency, he spent two years of dedicated research time at the Center for Biomedical Engineering developing a device for tissue engineering applications. That work then led to a National Science Foundation grant and a patent. Dr. Blakely then completed his fellowship in Complex General Surgical Oncology at City of Hope National Medical Center. His research focuses on evaluating the role of surgical debulking in multimetastatic gastrointestinal stromal tumor and in personalizing chemotherapy regimens for intraperitoneal treatment. He is the principal investigator for two active clinical treatment protocols, with more in development.
Series outline:
- Gastric cancer
- Appendiceal / Pseudomyxoma Peritonei
- Colorectal cancer
- Mesothelioma
- Ovarian Cancer / Gynecologic Malignancies
- Rare Histologies
Disclosure:
The series on “Peritoneal Carcinomatosis: History and Future” was commissioned by the editorial office, Digestive Medicine Research (DMR) without any sponsorship or funding. Andrew M. Blakely and Oliver S. Eng served as the unpaid Guest Editors for the series.
